# Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants

> **NCT07363837** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 36 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **DRUG:** SIBP-A16 injection
- **DRUG:** Nirsevimab
- **DRUG:** SIBP-A16 buffer solution

## Key facts

- **NCT ID:** NCT07363837
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07363837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07363837, "Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07363837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*